Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 164

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 164
---
      2023 |     | Change |           |
|:----------------------------------------|:----|:-------------|-----------:|:----|:--|----------:|:----|:-------|----------:|
| Direct program costs:                   |     |              |            |     |   |           |     |        |           |
| IFx-2.0                                 |     | $            |  7,286,319 |     | $ | 5,679,869 |     | $      | 1,606,450 |
| Preclinical research costs              |     |              |    702,627 |     |   |   316,178 |     |        |   386,449 |
| Indirect program costs:                 |     |              |            |     |   |           |     |        |           |
| Personnel and facilities related costs  |     |              |  5,346,370 |     |   | 3,406,370 |     |        | 1,940,000 |
| Total research and development expenses |     | $            | 13,335,316 |     | $ | 9,402,417 |     | $      | 3,932,899 |

Research and development expenses were $13.3 million and $9.4 million for the years ended December 31, 2024, and 2023, respectively. The increase of $3.9 million related to the following.

| • |     | an increase of approximately $1.6 million due to ongoing clinical development of IFx-2.0; |

| • |     | an increase of $0.4 million due to preclinical research of IFx-3.0 and MDSCs; and |

| • |     | an increase of $1.9 million in facilities, salary and personnel related costs. |

Acquired in process research and development (“IPR&D”). On January 26, 2023, we acquired certain assets of TuHURA Biopharma, for $1.2 million in cash and 4.1 million shares of Legacy TuHURA common stock. The common shares issued to TuHURA Biopharma had an estimated fair market value of $15.0 million. We performed the “screen test” and determined that substantially all of the fair value of the gross assets acquired in the TuHURA Biopharma acquisition was concentrated in a single identifiable asset or group of similar